Labcorp Reports Strong Q4 2025 Earnings Amid Divergent Biopharma Trends
Labcorp Holdings Inc. reported a 5.6% revenue increase to $3.5 billion in Q4 2025, driven by robust diagnostics volume and significant margin expansion. While the company achieved an 18% jump in adjusted EPS, performance was split between a surging Central Laboratory segment and a double-digit decline in Early Development services.